Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: An Insight from a phase II clinical study of zinpentraxin alfa

Geahča maid

• A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial
  Dahkki: Srdan Verstovsek, et al.
  Almmustuhtton: (2024-01-01)
• Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: An Insight from a phase II clinical study of zinpentraxin alfa
  Dahkki: Hosuk Ryou, et al.
  Almmustuhtton: (2024-06-01)
• The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies
  Dahkki: Vikas Gupta, et al.
  Almmustuhtton: (2016-12-01)
• Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis
  Dahkki: Ivo Veletic, et al.
  Almmustuhtton: (2020-07-01)
• Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
  Dahkki: Srdan Verstovsek, et al.
  Almmustuhtton: (2023-07-01)